Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2021 Oct;80(10):1351-1352.
doi: 10.1136/annrheumdis-2021-220656. Epub 2021 May 24.

High antibody response to two-dose SARS-CoV-2 messenger RNA vaccination in patients with rheumatic and musculoskeletal diseases

Jake A Ruddy #  1   2 , Caoilfhionn Marie Connolly #  2 , Brian J Boyarsky  1 , William A Werbel  3 , Lisa Christopher-Stine  2 , Jacqueline Garonzik-Wang  1 , Dorry L Segev  4   5 , Julie J Paik  2
Affiliations
Observational Study

High antibody response to two-dose SARS-CoV-2 messenger RNA vaccination in patients with rheumatic and musculoskeletal diseases

Jake A Ruddy et al. Ann Rheum Dis. 2021 Oct.
No abstract available

Keywords: COVID-19; autoimmune diseases; epidemiology; vaccination.

PubMed Disclaimer

Conflict of interest statement

Competing interests: DLS has the following financial disclosures: consulting and speaking honoraria from Sanofi, Novartis, CSL Behring, Jazz Pharmaceuticals, Veloxis, Mallincrodt and Thermo Fisher Scientific. LC-S has the following financial disclosures: consultant fees from Janssen, Boehringer-Ingelheim, Mallinckrodt, EMD-Serono, Allogene and ArgenX.

Figures

Figure 1.
Figure 1.
Anti-SARS-CoV-2 RBD antibody titer overall (n=403*) and by medications associated with a negative antibody response: mycophenolate included in regimen (n=41), rituximab included in regimen (n=19), glucocorticoid included in regimen (n=116), and glucocorticoid monotherapy (n=8) in patients with RMD after two-dose SARS-CoV-2 mRNA vaccination. Results range from <0.4 to >250 U/mL with positive antibody defined as an anti-SARS-CoV-2 RBD antibody titer >0.79 U/mL by the manufacturer; blue data points indicate median titer. * 1 titer value was missing from the total N (404).
See this image and copyright information in PMC

References

    1. Walsh EE, Frenck RW Jr, Falsey AR, et al. Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates. N Engl J Med 2020;383(25):2439–2450. doi:10.1056/NEJMoa2027906 - DOI - PMC - PubMed
    1. Widge AT, Rouphael NG, Jackson LA, et al. Durability of Responses after SARS-CoV-2 mRNA-1273 Vaccination. N Engl J Med 2021;384(1):80–82. doi:10.1056/NEJMc2032195 - DOI - PMC - PubMed
    1. Boyarsky BJ, Ruddy JA, Connolly CM, et al. Antibody response to a single dose of SARS-CoV-2 mRNA vaccine in patients with rheumatic and musculoskeletal diseases [published online ahead of print, 2021 Mar 23]. Ann Rheum Dis 2021;annrheumdis-2021–220289. doi:10.1136/annrheumdis-2021-220289 - DOI - PMC - PubMed
    1. Connolly CM, Boyarsky BJ, Ruddy JA, et al. Absence of Humoral Response After Two-Dose SARS-CoV-2 Messenger RNA Vaccination in Patients With Rheumatic and Musculoskeletal Diseases: A Case Series [in press]. Ann Intern Med 2021; M21–1451. - PMC - PubMed
    1. Higgins V, Fabros A, Kulasingam V. Quantitative Measurement of Anti-SARS-CoV-2 Antibodies: Analytical and Clinical Evaluation. J Clin Microbiol 2021;59(4):e03149–20. Published 2021 Mar 19. doi:10.1128/JCM.03149-20 - DOI - PMC - PubMed